These data suggest that kaempferol may be an effective therapeutic candidate to potentiate pancreatic cancer cell sensitivity to Erlotinib via the inhibition of EGFR and PI3K/AKT signaling [93]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.